Clinical Trial

A Phase 1 Study of AB521 Monotherapy and Combination Therapies in Renal Cell Carcinoma and Other Solid Tumors

Study acronym: ARC-20
Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The purpose of this study is to evaluate the safety and tolerability of: * casdatifan when taken alone in participants with advanced solid tumor malignancies and clear cell renal cell carcinoma (ccRCC) during the dose escalation stage; and * casdatifan monotherapy and casdatifan in combination with cabozantinib or zimberelimab or zimberelimab and ipilimumab in participants with ccRCC in the dose expansion stage.
Protocol Amendment History 1 change
notable Trial sites reduced: 29 -> 25 locations 2026-05-02
Trial Details
NCT Number NCT05536141
Lead Sponsor Arcus Biosciences, Inc.
Conditions Clear Cell Renal Cell Carcinoma, Solid Tumors
Enrollment 362 participants
Start Date 2022-10-26
Primary Completion 2029-03 (estimated)
Study Completion 2029-03 (estimated)
Updated on ClinicalTrials.gov 2026-07-29